Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. - Wikidata - awgldk - TriplyDB

Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.

Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.

http://www.wikidata.org/entity/Q35564174

about

TGF-beta1 stimulates human AT1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts Angiotensin signalling in pulmonary fibrosis Effects of ionizing radiation on biological molecules--mechanisms of damage and emerging methods of detection Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system.Metabolic spectroscopy of inflammation in a bleomycin-induced lung injury model using hyperpolarized 1-(13) C pyruvate.Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury.The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway.Novel therapeutic approaches for pulmonary fibrosis.Biological approaches to improve skeletal muscle healing after injury and disease Protective effects of angiotensin II interruption: evidence for antiinflammatory actions.Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.Epithelial-mesenchymal interactions in pulmonary fibrosis.Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy Expression of Angiotensin II and Aldosterone in Radiation-induced Lung Injury.Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats.The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats.Angiotensin II in apoptotic lung injury: potential role in meconium aspiration syndrome.ACE2, a promising therapeutic target for pulmonary hypertension.Genetic background of idiopathic pulmonary fibrosis.Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice.Mast cells: a pivotal role in pulmonary fibrosis.Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis.Passion fruit peel extract attenuates bleomycin-induced pulmonary fibrosis in mice.Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle.Impact of Olmesartan Medoxomil on Amiodarone-Induced Pulmonary Toxicity in Rats: Focus on Transforming Growth Factor-ß1.Treatment of pulmonary fibrosis with siRNA against a collagen-specific chaperone HSP47 in vitamin A-coupled liposomes.Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage.Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.Surfactant protein D is a useful biomarker for monitoring acute lung injury in rats.Activation of the renin-angiotensin system in hyperoxia-induced lung fibrosis in neonatal rats.Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD.Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-β and fibrosis in skeletal muscle injury.Differential expression of angiotensin receptors in human cutaneous wound healing.

P2860

Q24644667-0CC7677E-6480-444C-AFD1-D1335EE6A1A8 Q24804612-941D1181-D577-4432-9BB7-08E6277796F0 Q27025157-BA3E5E05-CF16-458E-B787-F60B3EDFA5EE Q33767975-DE3717F0-079A-4591-B8CD-92AE9C7E2542 Q33789538-4D9D05E3-A1FC-43FF-842C-ED2557735458 Q33946707-60ABF52C-1F89-470D-A516-8E64E5B61A3F Q34086852-16DAB963-1D14-4C15-B55D-89AD282AAAB4 Q34268946-52627315-20F4-482A-9BFE-748FEB5D4225 Q34811358-42A4D43D-382A-46E3-AD13-1E36055B9A31 Q34903224-707AC6D8-EE2C-47B7-9054-6186CAFE781F Q35180158-9572F882-4945-4DAD-ABAD-F36D659E3D4E Q36257966-43108475-B927-477D-8A6C-7519F19011D0 Q36264068-A7E9EC3F-ABBD-4F7E-BECF-69FBF91BF371 Q36427136-D687ECC3-22C0-4AA4-8568-C32A2EE5BB7A Q36440438-011093EB-A9CA-4B44-93E0-B2F54CB1FF3C Q36814443-672C77AA-799F-4E6F-8118-32905692209D Q36888683-6B09305E-C7A5-47E4-ABF5-5D6F4EE5943F Q36970923-88C344EB-2E1D-45F6-9DF8-C8E9443444AD Q37266352-0AFFB4B8-6133-46F4-9DC7-96C266227CD3 Q37341636-EB1106BD-067E-4360-9EBA-5B4D3AF5193C Q37826865-828FBD48-74A6-4BA0-8698-A3CDBF10E46D Q38103596-B8652933-8F64-449D-A616-366D860D3D9E Q38793048-CEEC8959-52C7-49DB-B2E0-500AA5FC1CF0 Q39802680-5D5BEB7C-6633-4C3F-BF50-3C7E55B1A762 Q40981994-9FC94EA5-6B81-4598-AA61-3086EE1C7D68 Q43753996-27F7476B-41DC-4F02-9E39-CEA719BBBF3F Q46542641-5D740F9B-27AC-4BA9-85AA-8BE03E44C708 Q46608132-9B73DF7E-F306-4B09-989D-3057C9297848 Q47649158-A18FE3AB-1FA7-47BB-82D0-30DD5CE7994F Q50540355-01139D08-B8B8-4FC6-A7F3-6FDD27C918A2 Q51233185-61B39C05-C0EB-450F-AD53-2E0F2F4C6D37 Q51468547-B3B0D852-565A-4385-86A3-AB68CD5FACBE Q51859653-AEAA2535-FB7C-4698-98EA-5A0C8FBCEC98 Q52643797-91B81805-784E-4F82-9739-78BE588AEBA9 Q53380133-BDB36528-D3D1-460F-93DD-BE0BF430659A Q54636220-41551A34-2CA7-4D54-B451-534C3E26A541

P2860

Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist.

http://www.wikidata.org/entity/Q35564174

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@ast

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@en

type

label

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@ast

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@en

prefLabel

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@ast

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@en

P1433

Q35564174-8D3646EE-2890-484E-8613-9B1562AB8CB2

P1476

Q35564174-E27947C5-1B81-421B-A559-169B346050A0

P2093

Q35564174-7F2C3301-E42E-498D-AEAD-994F3AA67AB6

Q35564174-9C745C61-F011-4D92-B72F-B0B0B6E09FCB

Q35564174-A67183D2-78D9-4388-A97C-27145402C5AD

Q35564174-D4621FC2-BCE5-463D-9651-DB76B99D8B10

Q35564174-D93EDA16-AEF0-4776-8B63-09A2E1D877D3

P2860

Q35564174-0616C49B-7F1E-434A-9FE8-CDA7BE285D8A

Q35564174-23331364-49B9-4D4F-A5F3-C6334793A0F3

Q35564174-376E3F8E-B715-47C1-A93A-EA9BE460CDAD

Q35564174-40F49442-B1EE-4420-B81B-1C6834C743E2

Q35564174-42B61A5E-60FC-41A0-9427-8D67A9D30AAE

Q35564174-54074D3F-246E-49F9-B97C-F969E37C68EB

Q35564174-57ACEFD8-381C-4215-AFE7-ED3832C47EFE

Q35564174-7BE378BA-7DD3-477A-ADF9-117EF9FE0EDD

Q35564174-7E0F2F1F-B56E-4031-96F8-88E620124354

Q35564174-824AA6A3-3435-4069-AE96-21C8351D19E0

P304

Q35564174-3A13D811-6783-4E79-8F62-45EB5F9A2F60

P31

Q35564174-D787CEE6-C9E1-4D57-B442-9A06927AE374

P356

Q35564174-D9535204-905B-4BEA-BFC0-8DC0AE22B966

P407

Q35564174-63AB4EDC-D4B6-4CDA-AEAE-86C3EFF64113

P433

Q35564174-F8C330A0-759C-485A-9DDD-13E2BCA8045B

P478

Q35564174-B4043115-4422-42F2-92E6-D4C0CF955A11

P577

Q35564174-A117B2B7-D393-4C05-B707-7F79FBE55C03

P5875

Q35564174-8DDEA899-C149-4356-B593-FE99B8B1DDEB

P698

Q35564174-ED515436-77DD-4CBF-BAE7-4E16F34443D5

P921

Q35564174-0611E704-CD75-48FC-A838-347B4DECAB7E

P932

Q35564174-D3EA78D0-53C5-432E-9CDE-6FF28E7B198F

P356

THX.2003.000893

P1433

P1476

Reduction of bleomycin induced ...... II type 1 receptor antagonist.

@en

P2093

H Chiba

http://www.w3.org/2001/XMLSchema#string

H Takahashi

http://www.w3.org/2001/XMLSchema#string

M Otsuka

http://www.w3.org/2001/XMLSchema#string

M Shiratori

http://www.w3.org/2001/XMLSchema#string

S Abe

http://www.w3.org/2001/XMLSchema#string

P2860

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta.

Kinetic alterations of angiotensin-II and nitric oxide in radiation pulmonary fibrosis.

Angiotensin II receptor antagonists.

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.

Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis

Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation.

Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin

Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor.

P304

31-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2003.000893

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2004-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277426260

http://www.w3.org/2001/XMLSchema#string

P698

14694243

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

1758867

http://www.w3.org/2001/XMLSchema#string